Skip Navigation

European Heart Journal 2000 21(7):521-532; doi:10.1053/euhj.1999.1882
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Berry, C
Right arrow Articles by Clark, A.L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berry, C
Right arrow Articles by Clark, A.L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review

Catabolism in chronic heart failure

C Berryf1 and A.L Clark

Department of Cardiology, Western Infirmary, North Glasgow Hospitals University NHS Trust, Glasgow, U.K.

revised August 3, 1999; accepted August 4, 1999

Key Words: Heart failure, catabolism, neurendocrine, cytokine, apoptosis, oxidative stress

f1 Correspondence: Dr C. Berry, MRC Clinical Training Fellow, Clinical Research Initiative in Heart Failure, Wolfson Building, Glasgow G12 8QQ, U.K. e-mail:colin.berry@clinmed.gla.ac.uk

References

  1. Poehlman ET, Scheffers J, Gottlieb SS, Fisher ML, Vaitekevicius P. Increased metabolic rate in patients with congestive heart failure. Ann Intern Med. 1994;121:860–862[Abstract/Free Full Text]
  2. Riley M, Elborn JS, McKane WR, Bell N, Stanford CF, Nicholls DP. Resting energy expenditure in chronic cardiac failure. Clin Sci. 1991;80:633–639[ISI][Medline]
  3. Lommi J, Kupari M, Yki-Jarvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol. 1998;81:45–50[CrossRef][ISI][Medline]
  4. Toth MJ, Gottlieb SS, Fisher ML, Poehlman ET. Daily energy requirements in heart failure patients. Metabolism. 1997;46:1294–1298[CrossRef][ISI][Medline]
  5. Toth MJ, Gottlieb SS, Fisher ML, Ryan AS, Nicklas BJ, Poehlman ET. Plasma leptin concentrations and energy expenditure in heart failure. Metab Clin Exp. 1997;46:450–453[Medline]
  6. Obisesan T, Toth MJ, Kendall D. Energy expenditure and symptom severity in men with heart failure. Am J Cardiol. 1996;77:1250–1252[CrossRef][ISI][Medline]
  7. Resnick H, Friedman B. Studies on the mechanism of the increased oxygen consumption in patients with cardiac disease. J Clin Invest. 1935;14:551–562[CrossRef][ISI][Medline]
  8. Opasich C, Pasini E, Aquilani R. Skeletal muscle function at low work level as a model for daily activities in patients with chronic heart failure. Eur Heart J. 1997;18:1626–1631[Abstract/Free Full Text]
  9. Mancini DM, Walter G, Reichnek N. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85:1364–1373[Abstract/Free Full Text]
  10. Simonini A, Long CE, Dudley GA, Yue P, McElhinny J, Massie BM. Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. Circ Res. 1996;79:128–136[Abstract/Free Full Text]
  11. Shane E, Mancini D, Aaronson K. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197–207[CrossRef][ISI][Medline]
  12. Anker S, Ponikowski P, Varney S. Wasting as an independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053[CrossRef][ISI][Medline]
  13. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in chronic heart failure: The central role of the periphery. J Am Coll Cardiol. 1996;28:1092–1102[Abstract]
  14. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978;41:233–243[CrossRef][ISI][Medline]
  15. Leimbach WN, Wallin G, Victor RG, Aylward PE, Sundolf G, Mark AL. Direct evidence from intraneural recordings of increased central sympathetic outflow in patients with heart failure. Circulation. 1986;73:913–919[Abstract/Free Full Text]
  16. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984;101:370–377[ISI][Medline]
  17. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299–305[Abstract/Free Full Text]
  18. Pederson EB, Danielson H, Jensen T, Madsen M, Sorenson SS, Thomsen OO. Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure. Eur J Clin Invest. 1986;16:56–60[ISI][Medline]
  19. Staroukine M, Devriendt J, Decoodt P, Verniory A. Relationships between plasma epinephrine, norepinephrine, dopamine, and angiotensin II concentrations, renin activity, hemodynamic state and prognosis in acute heart failure. Acta Cardiol. 1984;39:131–138[ISI][Medline]
  20. McMurray JJV, Ray SG, Abdullah I, Dargie HD, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374–1379[Abstract/Free Full Text]
  21. Tsutamoto T, Hisanaga T, Fukai D. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 in patients with chronic congestive cardiac failure. Am J Cardiol. 1995;76:803–808[CrossRef][ISI][Medline]
  22. Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M. Activation of neurohormonal systems in post-infarction left ventricular dysfunction. J Am Coll Cardiol. 1993;22:390–398[Abstract]
  23. Francis GS, Benedict C, Johnstone DE. Comparison of neurendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation. 1990;82:1724–1729[Abstract/Free Full Text]
  24. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M. Prognostic significance of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583–589[Abstract]
  25. Benedict CR, Shelton B, Johnstone DE. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724–1729[Abstract/Free Full Text]
  26. Vantrimpont P, Rouleau JL, Ciampi A. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J. 1998;19:1552–1563[Abstract/Free Full Text]
  27. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730–1736[Abstract/Free Full Text]
  28. Chritin L, O'Connell M, Bogardus C, Danforth E Jr, Ravussen E. Norepinephrine turnover and energy expenditure in Pima Indians and white men. Metab Clin Exp. 1993;426:723–729
  29. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor in rats through a pressor-independent mechanism. J Clin Invest. 1996;97:2509–2516[ISI][Medline]
  30. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790–804[Abstract/Free Full Text]
  31. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185–1195[Abstract/Free Full Text]
  32. Rajagopalan S, Kurz S, Munzel T. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to vasomotor tone. J Clin Invest. 1996;97:1916–1923[ISI][Medline]
  33. Bech Laursen J, Rajagopalan S, Galis Z. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588–593[Abstract/Free Full Text]
  34. Berry C, Hamilton CA, Brosnan MJ. An investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000;:
  35. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. P22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;271:23317–23321[Abstract/Free Full Text]
  36. Kajstura J, Cigola E, Malhotra A. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859–870[CrossRef][ISI][Medline]
  37. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells: Protective effect of nitric oxide. Circ Res. 1997;81:970–976[Abstract/Free Full Text]
  38. Horiuchi M, Hayashida W, Katambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates BcL-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem. 1997;272:19022–19026[Abstract/Free Full Text]
  39. Cigola E, Kajustura J, Baosheng L, Meggs LG, Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res. 1997;231:363–371[CrossRef][ISI][Medline]
  40. Severn A, Rapson NT, Hunter CA, Liew FY. Regulation of tumour necrosis factor production by adrenaline and ß-adrenergic agonists. J Immunol. 1992;148:3441–3445[Abstract]
  41. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure. Circulation. 1994;90:1774–1780[Abstract/Free Full Text]
  42. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–241[Abstract]
  43. McMurray JJV, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor alpha in ‘cachectic’ patients with severe heart failure. Br Heart J. 1991;66:356–358[Abstract/Free Full Text]
  44. Steele IC, Nugent AM, Hoper M, Campbell G, Halliday MI, Nicholls DP. Cytokine profile in chronic heart failure. Eur J Clin Invest. 1996;36:1018–1022
  45. Katz SD, Rao R, Berman JW. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide dependent vasodilation in the forearm circulation. Circulation. 1994;90:12–16[Abstract/Free Full Text]
  46. Blum A, Sclarovsky S, Rehavia E, Shohat B. Levels of T lymphocyte subpopulations, interleukin 1 beta, and soluble interleukin 2 receptor in acute myocardial infarction. Am Heart J. 1994;127:1226–1230[CrossRef][ISI][Medline]
  47. Marriott JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart. 1998;75:287–290
  48. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor alpha. J Am Coll Cardiol. 1993;22:1897–1901[Abstract]
  49. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J. 1998;19:761–765[Abstract/Free Full Text]
  50. Ferrari R, Bachetti T, Confortini R. Tumour necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92:1479–1486[Abstract/Free Full Text]
  51. Anker SD, Egerer KR, Volk H-D, Kox WJ, Poole-Wilson PA, Coats AJS. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 1997;79:1426–1430[CrossRef][ISI][Medline]
  52. Blum A, Miller. Role of cytokines in heart failure. Am Heart J. 1998;135:181–186[CrossRef][ISI][Medline]
  53. Aukrust P, Ueland T, Muller F. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998;97:1136–1143[Abstract/Free Full Text]
  54. Torre-Amione G, Kapadia S, Benedict G. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206[Abstract]
  55. Noutsias M, Seeberg B, Schultheiss HP, Kuhl U. Expression of cell adhesion molecules in dilated cardiomyopathy. Circulation. 1999;99:2124–2131[Abstract/Free Full Text]
  56. Oppenheimer MN, Davis LS, Bogue DT, Ramberg J, Lipsky PE. Differential utilisation of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol. 1991;147:2913–2921[Abstract]
  57. Leyva F, Anker SD, Godsland IF. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998;19:1814–1822[Abstract/Free Full Text]
  58. Yan SF, Ogawa S, Stern DM, Pinsky DJ. Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Kidney Int. 1997;51:419–425[ISI][Medline]
  59. Sluiter W, Pietersma A, Lamers JM, Korster JF. Leucocyte adhesion molecules and the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J Cardiovasc Pharmacol. 1993;22:S37–44
  60. Phan SH, Gannon DE, Varani J, Ryan US, Ward PA. Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils. Am J Pathol. 1989;134:1201–1211[Abstract]
  61. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994; 45;:491–503
  62. Matthys P. Cytokines and cachexia. Nutrition. 1997;13:763–770[CrossRef][ISI][Medline]
  63. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, co-stimulation and death. Cell. 1994;76:959–962[CrossRef][ISI][Medline]
  64. Aderka D, Engelmann H, Maor Y. Stabilisation of the bioactivity of tumour necrosis factor by its soluble receptors. J Exp Med. 1992;175:323–329[Abstract/Free Full Text]
  65. Milani RV, Mehra MR, Endres S. The clinical relevance of circulating tumour necrosis factor-{alpha} in acute decompensated chronic heart failure without cachexia. Chest. 1996;110:992–995[CrossRef][ISI][Medline]
  66. Zhao SP, Zeng LH. Elevated plasma levels of tumour necrosis factor in chronic heart failure with cachexia. Int J Cardiol. 1997;58:257–261[CrossRef][ISI][Medline]
  67. Anker SD, Chua T, Ponikowski P. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–534[Abstract/Free Full Text]
  68. Anker SD, Clark AL, Kemp M. Tumour necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol. 1997;30:997–1001[Abstract]
  69. Torre-Amione G, Kapadia S, Lee J. Tumour necrosis factor-{alpha} and tumour necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711[Abstract/Free Full Text]
  70. Heller RA, Song K, Onasch MA. Complementary DNA cloning of a receptor for tumour necrosis factor and demonstration of a shed of the receptor. Proc Natl Acad Sci. 1990;87:6151–6155[Abstract/Free Full Text]
  71. Samsonov M, Lopatin J, Tilz GP. The activated immune system and he renin-angiotensin-aldosterone system in congestive heart failure. J Int Med. 1998;243:93–98[CrossRef][ISI][Medline]
  72. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 1990;275:87–90[CrossRef][ISI][Medline]
  73. Gross, SS, Jaffe, EA, Levi, R, Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is a tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank order of potency characteristic of activated macrophages, Biochem Biophys Res Commun, 1991, 178, 823, 9
  74. Katz, SD, Rao R, Berman JW. Pathophysiological correlates of increased serum tumour necrosis factor in patients with congestive heart failure. Circulation. 1994;90:12–16[Abstract/Free Full Text]
  75. Krown KA, Page MT, Nguyen C. Tumour necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854–2865[ISI][Medline]
  76. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998;274:577–595
  77. Parissis JT, Venetsanou KF, Ziras NG. Evaluation of soluble forms of apoptotic receptors Fas and TNFRI in congestive heart failure. Hellenic J Cardiol. 1998;39:312–319
  78. Nishigaki K, Minatoguchi S, Seishima M. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. J Am Coll Cardiol. 1997;29:1214–1220[Abstract]
  79. Sedlak TW, Oltavi ZN, Yang E. Multiple Bcl-2 family members demonstrate selective dimerisations with Bax. Proc Natl Acad Sci. 1995;92:7834–7838[Abstract/Free Full Text]
  80. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Acute treatment with tumour necrosis factor-{alpha} induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem. 1993;125:11–18[CrossRef][ISI][Medline]
  81. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest. 1985;76:1539–1553[ISI][Medline]
  82. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest. 1995;95:677–685[ISI][Medline]
  83. Suffredini AF, Frinnm RE, Parker MM. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280–287[Abstract]
  84. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor alpha in the adult mammalian heart. J Clin Invest. 1993;92:2303–2312[ISI][Medline]
  85. Bryant D, Becker L, Richardson J. Cardiac failure in transgenic mice with myocardial expression of tumour necrosis factor-{alpha}. Circulation. 1998;97:1375–1381[Abstract/Free Full Text]
  86. Kubota T, McTiernan CF, Frye CS. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumour necrosis factor-{alpha}. Circ Res. 1997;81:627–635[Abstract/Free Full Text]
  87. Bristow MR. Tumour necrosis factor-{alpha} and cardiomyopathy. Circulation. 1998;97:1340–1341[Free Full Text]
  88. Lenardo MJ, Baltimore D. NF kappa B: a pleiotropic mediator of inducible and tissue specific gene control. Cell. 1989;58:227–229[CrossRef][ISI][Medline]
  89. Barnes PJ, Karin M. Nuclear factor-{kappa}B—a pivotal transcription factor in chronic inflammatory disease. N Engl J Med. 1997;336:1066–1071[Free Full Text]
  90. Satriano J, Schlondorff D. Activation and attenuation of transcription factor NF{kappa}B in the mouse glomerular mesangial cells in response to tumour necrosis factor-{alpha}, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J Clin Invest. 1994;94:1629–1636[ISI][Medline]
  91. Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol. 1986;137:3295–3298[Abstract]
  92. Xie QW, Kashiwabarata Y, Nathan C. Role of transcription factor NF{kappa}B/RcL in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705–4708[Abstract/Free Full Text]
  93. Yamamoto K, Arkawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor C and nuclear factor-interleukin-6 in the tumour necrosis factor {alpha}-dependent induction of cycloxoygenase-2 in MC3T3 -E1 cells. J Biol Chem. 1995;270:31315–31320[Abstract/Free Full Text]
  94. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the cycloxygenase-2 gene. J Biochem. 1994;302:723–727
  95. Curtis MJ, Pugsley MK, Walker MJ. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res. 1993;27:703–719[Free Full Text]
  96. Wong SC, Fukuchi M, Melnyk P, Rodger I, Giaid A. Induction of cox-2 and activation of NF{kappa}B in myocardium of patients with congestive heart failure. Circulation. 1998;96:100–103
  97. Simonini A, Long CA, Dudley GA, Yue P, McElhinney J, Massie BM. Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced physical activity. Circ Res. 1996;79:128–136[Abstract/Free Full Text]
  98. Tracey KJ, Morgello S, Koplin B. Metabolic effects of cachectin/ tumour necrosis factor are modified by site of production: cachectin/tumour necrosis factor-secreting tumour in skeletal muscle induces chronic cachexia, while implantation in brain induces predominately acute anorexia. J Clin Invest. 1990;86:2014–2024[ISI][Medline]
  99. Berkowitz DE, Brown D, Lee KM. Endotoxin-induced alteration in the expression of leptin and beta-3 adrenergic receptor in adipose tissue. Am J Physiol. 1998;274:992–997
  100. Mantzoros CS, Moschos S, Avramopoulos I. Leptin concentrations in relation to body mass index and the tumour necrosis factor-alpha system in humans. J Clin Endocrinol Metab. 1997;82:3408–3413[Abstract/Free Full Text]
  101. Thomson A. The Cytokine Handbook, 2nd edn. : Academic Press; 1994.
  102. Patten M, Hartogenesis WE, Long CS. Interleukin-1 beta is a negative transcriptional regulator of alpha-1 adrenergic induced gene expression in cultured cardiac myocytes. J Biol Chem. 1996;271:21134–21141[Abstract/Free Full Text]
  103. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30:215–223[CrossRef][ISI][Medline]
  104. Xin X, Cai Y, Matsumoto K, Agui T. Endothelin induced interleukin 6 production by rat aortic endothelial cells. Endocrinology. 1995;136:1322–1327
  105. Goodman MN. Interleukin 6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med. 1994;205:182–185[Abstract]
  106. Tsujinaka T, Fujita J, Ebisui C. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996;97:244–249[ISI][Medline]
  107. Libert C, Brouckaert P, Shaw A, Fiers W. Induction of interleukin-6 by human and murine recombinant interleukin-1 in mice. Eur J Immunol. 1990;20:691–694[ISI][Medline]
  108. Tsutamoto T, Hisanaga T, Wada A. Interleukin 6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin 6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:391–398[Abstract/Free Full Text]
  109. Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65:235–248
  110. Li Y, Huang T, Carlson EJ. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganes superoxide dismutase. Nature Gen. 1995;11:376–379[CrossRef][ISI][Medline]
  111. Nishiyama Y, Ikeda H, Haramaki N, Yoshida N, Imaizumi T. Oxidative stress is related to exercise intolerance in patients with heart failure. Am Heart J. 1998;135:115–120[CrossRef][ISI][Medline]
  112. Keith M, Geranmayegan A, Sole MJ. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:1352–1356[Abstract/Free Full Text]
  113. MacLellan RW, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 1997;81:137–144[Abstract/Free Full Text]
  114. Haunstetter A, Izumo S. Apoptosis. Basic mechanisms and implications for cardiovascular disease. Circ Res. 1998;82:1111–1129[Free Full Text]
  115. Anversa P, Kajstura J. Myocyte cell death in the diseased heart. Circ Res. 1998;82:1231–1233[Free Full Text]
  116. Narula J, Haider N, Virmani R. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182–1189[Abstract/Free Full Text]
  117. Olivetti G, Abbi R, Quaini F. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131–1141[Abstract/Free Full Text]
  118. Saraste A, Voipio-Pulkki L-M, Parvinen M, Pulkki K. Apoptosis in the heart. N Engl J Med. 1997;336:1025–1026[Free Full Text]
  119. Tanaka M, Ito H, Adachi S. Hypoxia induces apoptosis with enhanced expression of fas antigen messenger RNA in cultured neonatal rat cardiocytes. Circ Res. 1994;75:426–433[Abstract/Free Full Text]
  120. Gottlieb RA, Burleson RA, Kloner BM, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621–1628[ISI][Medline]
  121. Landerhoutte KR, Webster KA. Hypoxia/reoxygenation stimulates jun kinase activity through redox signaling in cardiac myocytes. Circ Res. 1997;80:336–344[Abstract/Free Full Text]
  122. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326–1331[Abstract/Free Full Text]
  123. Teiger E, Dam TV, Richard L. Apoptosis in pressure overload-induced hypertrophy in the rat. J Clin Invest. 1996;97:2891–2897[ISI][Medline]
  124. Cheng W, Li B, Kajstura J, Li P. Stretch-induced programmed myocyte cell death. J Clin Invest. 1995;96:2247–2259[ISI][Medline]
  125. Liu Y, Cigola E, Cheng W. Myocyte nuclear mitotic division and programmed myocyte cell death characterise the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest. 1995;73:771–787[ISI][Medline]
  126. Wu CF, Bishop NH, Pratt RE. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiocytes. J Biol Chem. 1997;272:14860–14866[Abstract/Free Full Text]
  127. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998;83:516–522[Abstract/Free Full Text]
  128. Toyozaki T, Hiroe M, Saito T. Levels of soluble fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers. Am J Cardiol. 1998;81:798–800[CrossRef][ISI][Medline]
  129. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJS. Insulin resistance in chronic heart failure. Eur Heart J. 1994;15:1528–1532[Abstract/Free Full Text]
  130. Lommi J, Kupari M, Koskinen P. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol. 1996;28:665–672[Abstract]
  131. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994;15:555–573[Abstract]
  132. Giustina A, Lorusso R, Borghetti V, Bugari G, Misitano V, Alfieri O. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy. Am Heart J. 1996;131:622–623[CrossRef][ISI][Medline]
  133. Niebauer J, Pflaum C-D, Clark AL. Deficient insulin-like growth factor-I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol. 1998;32:393–397[Abstract/Free Full Text]
  134. Wu Y, Tewari M, Cui S, Rubin R. Activation of the insulin-like growth factor-I receptor inhibits tumour necrosis factor-induced cell death. J Cell Physiol. 1996;168:499–509[CrossRef][ISI][Medline]
  135. Resnicoff M, Abraham D, Yutanawiboonchai W. The insulin-like growth factor receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995;55:2463–2469[Abstract/Free Full Text]
  136. Resnicoff M, Burgaud JL, Rotman HL, Abraham D, Baserga R. Correlation between apoptosis, tumorigenesis, and levels of insulin-factor I receptors. Cancer Res. 1995;55:3739–3741[Abstract/Free Full Text]
  137. Amato G, Carella C, Fazio S. Body composition, bone metabolism, heart structure and function in growth hormone deficiency adults before and after growth hormone replacement therapy. J Clin Endocrinol Metab. 1993;77:1671–1676[Abstract]
  138. Yang R, Bunting S, Gillet N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262–267[Abstract/Free Full Text]
  139. Fazio S, Sabatini D, Capaldo B. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809–814[Abstract/Free Full Text]
  140. Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sonkersen PH. Cardiac failure responding to growth hormone. Lancet. 1989;1:838–839[CrossRef][ISI][Medline]
  141. Osterziel KJ, Strohm O, Schuler J. Randomised, double-blind, placebo controlled trial of human recombinant growth hormone in patients with chronic heart failure. Lancet. 1998;35:1233–1237
  142. Swan JW, Anker SD, Walton C. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30:527–532[Abstract]
  143. Baron AD. Hemodynamic actions of insulin. Am J Physiol. 1994;267:E187–E202[ISI][Medline]
  144. Houghton AR, Harrison M, Perry AS, Evans AJ, Cowley AJ. Endogenous insulin and insulin sensitivity. An important determinant of skeletal muscle blood flow in chronic heart failure. Eur Heart J. 1998;19:476–480[Abstract/Free Full Text]
  145. Pelleymounter MA, Cullen MJ, Baker MB. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;268:540–543[Abstract/Free Full Text]
  146. Halaas JL, Gajiwala KS, Maffrei M. Weight reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543–546[Abstract/Free Full Text]
  147. Stephens TW, Basinksi M, Bristow PK. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995;377:530–532[CrossRef][Medline]
  148. Prins JB, O'Rahilly S. Regulation of adipose cell number in man. Clin Sci. 1997;92:3–11[Medline]
  149. Maisel AS, Scott NA, Motulsky HJ. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 1989;86:43[CrossRef][ISI][Medline]
  150. Potter EK. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther. 1988;32:251
  151. Kennedy A, Gettys TW, Watson P. The metabolic significance of leptin in humans: gender based differences in relation to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab. 1997;82:1293–1300[Abstract/Free Full Text]
  152. Haffner SM, Miettinen H, Mykkanen L, Karhappaa P, Rainwater DL, Laasko M. Leptin concentrations and insulin sensitivity in normoglycaemic men. Int J Obes. 1997;21:393–399[CrossRef][ISI][Medline]
  153. Leyva F, Anker SD, Egerer K, Stevenson JC, Knox WJ, Coats AJS. Hyperleptinaemia in chronic heart failure; relationships with insulin. Eur Heart J. 1998;19:1547–1551[Abstract/Free Full Text]
  154. Leroy P, Dessolin S, Villageois P. Expression of ob gene in adipose cells. Regulation by insulin. J Biol Chem. 1996;271:2365–2368[Abstract/Free Full Text]
  155. Cusin I, Sainsbury A, Doyle P, Rohner-Jeanrenaud F, Jeanrenaud B. The ob gene and insulin. A relationship leading to clues to the understanding of obesity. Diabetes. 1995;44:1467–1470[Abstract]
  156. Murdoch DR, Rooney E, Dargie HJ, Shapiro D, Morton JJ, McMurray JJV. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart. 1999;823:352–356
  157. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990;16:91–95[Abstract]
  158. Chopra IJ, Hershman JM, Pardridge WM, Nicoloff JT. Thyroid function in non-thyroidal illness. Ann Int Med. 1983;98:946–947[ISI][Medline]
  159. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990;88:626–630[CrossRef][ISI][Medline]
  160. Morkin E, Flink IL, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovasc Dis. 1983;25:435–464[CrossRef][ISI][Medline]
  161. Klein I, Levey GS. New perspectives on thyroid hormone, catecholamines, and the heart. Am J Med. 1984;76:167–172[CrossRef][ISI][Medline]
  162. Moruzzi P, Doria E, Agostoni PG, Capacchione V, Sganzerla P. Usefulness of L thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:374–378[CrossRef][ISI][Medline]
  163. Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1989;63:709–713[CrossRef][ISI][Medline]
  164. Broqvist M, Arnqvist H, Dahlstrom U, Larsson J, Nylander E, Permert J. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure-effects of long-term dietary supplementation. Eur Heart J. 1994;15:1641–1650[Abstract/Free Full Text]
  165. King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996;25:144–149[Abstract/Free Full Text]
  166. King D, Smith ML, Lye M. Gastro intestinal protein loss in elderly patients with cardiac cachexia. Age Ageing. 1996;25:221–223[Abstract/Free Full Text]
  167. Katz AM, Katz PB. Disease of the heart in works of Hippocrates. Br Heart J. 1962;24:257–262[Abstract/Free Full Text]
  168. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev. 1991;49:163–175[ISI][Medline]
  169. Morrison WL, Gibson JN, Rennie MJ. Skeletal muscle and whole body protein turnover in cardiac cachexia: influence of branched chain amino acid administration. Eur J Clin Invest. 1988;18:648–654[ISI][Medline]
  170. Anker SD, Swan JW, Volterrani M. The influence of muscle mass, strength, fatiguability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1997;18:259–269[Abstract/Free Full Text]
  171. Piepoli M, Clark AL, Coats AJS. Muscle metaboreceptors in the hemodynamic, autonomic and ventilatory responses to exercise in man. Am J Physiol. 1995;269:H1428–1436[Medline]
  172. N Engl J Med. 1987;316:1429–1435[Abstract]
  173. N Engl J Med. 1991;325:293–302[Abstract]
  174. Packer M, Bristow MR, Cohn JN. The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  175. Lancet. 1999;353:9–13[CrossRef][ISI][Medline]
  176. Lancet. 1999;353:2001–2007[CrossRef][ISI][Medline]
  177. Minotti JR, Johnson EC, Hudson TL. Training-induced skeletal muscle adaptations are independent of systemic adaptations. J Appl Physiol. 1990;68:289–294[Abstract/Free Full Text]
  178. Eur Heart J. 1998;19:466–475[Abstract/Free Full Text]
  179. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomised, controlled trial of long-term moderate exercise training in chronic heart failure. Circulation. 1999;99:1173–1182[Abstract/Free Full Text]
  180. Lanore JJ, Dhainaut JF, Fisher CJ. Effects of and anti-TNF IgG monoclonal antibody on left ventricular performance in septic patients. Intens Care Med. 1992;18:S49
  181. Boekstegers P, Weidenhofer S, Zell R. Repeated administration of a F(ab[prime]2 fragment of an anti-tumour necrosis factor alpha-monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock. 1994;1:237–245[ISI][Medline]
  182. JAMA. 1982;247:1707–1714[Abstract]
  183. Yue TL, Cheng HY, Lysko PG. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an anti-oxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92–98[Abstract/Free Full Text]
  184. Kukin ML, Kalman J, Charney RH. Prospective, randomised comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99:2645–2651[Abstract/Free Full Text]
  185. Yue TL, Ma KL, Wang X. Possible involvement of stress-activated protein kinase signal pathway and fas receptor expression in prevention of ischaemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res. 1998;82:166–174[Abstract/Free Full Text]
  186. Ruffolo R, Feuerstein GZ. Pharmacology of carvedilol: rational for use in hypertension, coronary artery disease and congestive heart failure. Cardiovasc Drug Ther. 1997;11:247–256[Medline]
  187. Goussev A, Sharov VG, Shimonoyama H. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol. 1998;275:H626–631[ISI][Medline]
  188. Gullestad L, Aukrust P, Ueland T. Effect of high versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34::2061–2067[Medline]
  189. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
S. Kenchaiah, S. J. Pocock, D. Wang, P. V. Finn, L. A.M. Zornoff, H. Skali, M. A. Pfeffer, S. Yusuf, K. Swedberg, E. L. Michelson, et al.
Body Mass Index and Prognosis in Patients With Chronic Heart Failure: Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program
Circulation, August 7, 2007; 116(6): 627 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. von Haehling, W. Doehner, and S. D Anker
Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure
Cardiovasc Res, January 15, 2007; 73(2): 298 - 309.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Aquilani, C. Opasich, M. Dossena, P. Iadarola, A. Gualco, P. Arcidiaco, S. Viglio, F. Boschi, M. Verri, and E. Pasini
Increased skeletal muscle amino acid release with light exercise in deconditioned patients with heart failure
J. Am. Coll. Cardiol., January 4, 2005; 45(1): 158 - 160.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Aquilani, C. Opasich, M. Verri, F. Boschi, O. Febo, E. Pasini, and O. Pastoris
Is nutritional intake adequate in chronic heart failure patients?
J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1218 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A.L. Clark, M. Loebe, E.V. Potapov, K. Egerer, C. Knosalla, R. Hetzer, and S.D. Anker
Ventricular assist device in severe heart failure. Effects on cytokines, complement and body weight
Eur. Heart J., December 2, 2001; 22(24): 2275 - 2283.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
K. K. A. Witte, A. L. Clark, and J. G. F. Cleland
Chronic heart failure and micronutrients
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1765 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Berry
Clinical implications of increased plasma angiotensin II concentrations despite ACE inhibitor therapy in patients with congestive heart failure: the issue of non-compliance with therapy
Eur. Heart J., September 1, 2000; 21(17): 1484 - 1485.
[PDF]

Home page
 Eur Heart JHome page
C. Berry
Clinical implications of increased plasma angiotensin II concentrations despite ACE inhibitor therapy in patients with congestive heart failure: the issue of non-compliance with therapy
Eur. Heart J., September 1, 2000; 21(17): 1484 - 1485.
[PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Berry, C
Right arrow Articles by Clark, A.L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berry, C
Right arrow Articles by Clark, A.L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?